Modelling relapse in patients with high-risk localised prostate cancer treated randomly in the GETUG 12 phase III trial reveals two populations of relapsing patients
Cécile Vicier(Aix-Marseille Université), Karim Fizazi(Université de Lille), Brigitte Laguerre(Centre Eugène Marquis), Laurence Faivre(Inserm), Marjorie Baciuchka, Stéphane Culine(Hôpital Saint-Louis), I. Krakowski, Frank Priou, Stéphane Oudard(Assistance Publique – Hôpitaux de Paris), Nadine Houédé(Inserm), Gwénaëlle Gravis(Centre National de la Recherche Scientifique), Muriel Habibian, F. Lesaunier, Christine Théodore(Hôpital Foch), R. Delva, J.F. Berdah(Hôpital Sainte-Marguerite), F. Rolland(Institut de Cancérologie de l'Ouest), Aude Fléchon(Institut Català d'Ornitologia), J-M Ferrero(Centre Antoine Lacassagne), Loı̈c Mourey
Cited by 0
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k